Company
Headquarters: Taipei, Taiwan
CEO: Dr. Yuxin Lin M.B.A., Ph.D.
TW$33.01 Billion
TWD as of Jan. 1, 2026
US$1.05 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (AMD) and stargardt diseases; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei City, Taiwan.
Lin BioScience, Inc. has the following listings and related stock indices.
Stock: TWSE: 6696 wb_incandescent
Stock: MYX: 5789 wb_incandescent